Gene Biotherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Cash used in financing activities reached the amount of $0 last year.
Cash Flow
| 2013 | -6.02M | -23.05K | 3.74M |
|---|---|---|---|
| 2014 | -2.46M | 0 | 2.65M |
| 2015 | -1.05M | 0 | 857.70K |
| 2016 | -2.02M | -171.72K | 3.10M |
| 2017 | -1.06M | 0 | 180.98K |
| 2018 | -451.50K | 650K | -165.37K |
| 2019 | -137.16K | 0 | 55.44K |
| 2020 | -1.13M | -3.43K | 1.52M |
| 2021 | 0 | 0 | 0 |
| 2022 | 0 | 0 | 0 |
CRXM Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 0 | 386.02K | 400 | 82.11K | 48.98K | 930.39K | 21.54K | 216.73K | 22.48K | 2.32M |
Operating activities | ||||||||||
Net income | 0 | 0 | -651.55K | 779.12K | -552.74K | -2.09M | -3.01M | -3.69M | -5.50M | -8.91M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 1.81K | 58.17K | 63.20K | 66.08K | 20.02K | 9.88K | 13.78K | 296.44K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 803 | 518.47K | 985.11K | 508.62K | 40.75K |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 803 | 518.47K | 985.11K | 508.62K | 40.75K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 222.11K |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 620.69K |
Accounts payable | 0 | 0 | -153.52K | 77.51K | -12.26K | 197.15K | -117.71K | 586.34K | 214.02K | 517.49K |
Cash generated by operating activities | 0 | 0 | -1.13M | -137.16K | -451.50K | -1.06M | -2.02M | -1.05M | -2.46M | -6.02M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | 0 | -3.43K | 0 | 0 | 0 | -171.72K | 0 | 0 | -23.05K |
Acquisitions Net | 0 | 0 | 0 | 0 | 650K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 0 | -3.43K | 0 | 650K | 0 | -171.72K | 0 | 0 | -23.05K |
Financing activities | ||||||||||
Common Stock Issued | 0 | 0 | 600K | 0 | 0 | 0 | 3M | 600K | 2.12M | 6.39M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -204.52K | 55.44K | -194.61K | 180.98K | -104.18K | 257.70K | 0 | 0 |
Cash used in financing activities | 0 | 0 | 1.52M | 55.44K | -165.37K | 180.98K | 3.10M | 857.70K | 2.65M | 3.74M |
Net Change In Cash | 0 | 0 | 385.62K | -81.71K | 33.12K | -881.40K | 908.85K | -195.18K | 194.24K | -2.30M |
Cash at end of period | 0 | 386.02K | 386.02K | 400 | 82.11K | 48.98K | 930.39K | 21.54K | 216.73K | 22.48K |
| Data source | Data source | Data source | Data source | Data source | Data source |